Mycobacteria and autoimmunity

Lupus

Volumn 24, Issue , 2015, Pages 374-381

  Machado Ribeiro, F ^a   Goldenberg, T ^b  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

autoantibodies; immunosuppressive therapies; molecular mimicry; mycobacteria; nontuberculous mycobacteria; Tuberculosis

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; GAMMA INTERFERON; HEAT SHOCK PROTEIN 110; IMMUNOSUPPRESSIVE AGENT; MITOCHONDRION ANTIBODY; VITAMIN D; VITAMIN D RECEPTOR;

AFRICAN; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; DISEASE ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; INFECTION RISK; INFLAMMATORY DISEASE; INTERFERON PRODUCTION; META ANALYSIS (TOPIC); MIXED INFECTION; MYCOBACTERIUM GORDONAE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SEX DIFFERENCE; SIBLING; SYSTEMIC DISEASE; TUBERCULOSIS; X CHROMOSOME; ANIMAL; IMMUNOLOGY; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; PATHOGENICITY;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; TUBERCULOSIS;

EID: 84925691066     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314559634     Document Type: Article

References (99)

1. Lyons AS Medicine: An illustrated history. Lyons AS Petrucelli RJ, ed. New York: Abradale Press ; 1987: 121-152.
2. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007 ; 175: 367-416
3. WHO Global tuberculosis control: Surveillance, planning, financing. The WHO Global tuberculosis report 2013. http://www.who.int/tb/publications/global-report/en/index.html (accessed 29 August 2014).
4. Barnes HL, Branes IR. The duration of life in pulmonary tuberculosis with cavity. Trans Am Climatol Clin Assoc. 1928 ; 44: 39-55
5. Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ. Natural history of tuberculosis: Duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: A systematic review. PLoS One. 2011 ; 6: e17601 - e17601
6. DeRiemer K, Kawamura LM, Hopewell PC, Daley CL. Quantitative impact of human immunodeficiency virus infection on tuberculosis dynamics. Am J Respir Crit Care Med. 2007 ; 176: 936-944
7. Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recommend Rep. 2009 ; 58: 1-207
8. Horsburgh CR. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med. 2004 ; 350: 2060-2067
9. Kwan CK, Ernst JD. HIV and tuberculosis: A deadly human syndemic. Clin Microbiol Rev. 2011 ; 24: 351-376
10. Barksdale L, Kim KS. Mycobacterium. Bacteriol Rev. 1977 ; 41: 217-372
11. Ratogi N, David HL. Mechanisms of pathogenicity in mycobacteria. Biochimie. 1988 ; 70: 1101-1120
12. Philips JA, Ernst JD. Tuberculosis pathogenesis and immunity. Annu Rev Pathol. 2012 ; 7: 353-384
13. Thoma-Uszynski S, Stenger S, Takeuchi O, et al. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science. 2001 ; 291: 1544-1547
14. Brightbill HD, Libraty DH, Krutzik SR, et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science. 1999 ; 285: 732-736
15. Rocha-Ramírez LM, Estrada-García I, López-Marín LM, et al. Mycobacterium tuberculosis lipids regulate cytokines, TLR-2/4 and MHC class II expression in human macrophages. Tuberculosis (Edinb). 2008 ; 88: 212-220
16. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006 ; 124: 783-801
17. Janeway CA, Medzhitov R. Innate immune recognition. Ann Rev Immunol. 2002 ; 20: 197-216
18. Mills KHG. TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol. 2011 ; 11: 807-822
19. Yuan Y, Crane DD, Barry CE. Stationary phase-associated protein expression in Mycobacterium tuberculosis: Function of the mycobacterial alpha-crystallin homolog. J Bacteriol. 1996 ; 178: 4484-4492
20. Yuan Y, Crane DD, Simpson RM, et al. The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages. Proc Natl Acad Sci USA. 1998 ; 95: 9578-9583
21. Lin MY, Reddy TB, Arend SM, et al. Cross-reactive immunity to Mycobacterium tuberculosis DosR regulon-encoded antigens in individuals infected with environmental, nontuberculous mycobacteria. Infect Immun. 2009 ; 77: 5071-5079
22. Bellamy R, Beyers N, McAdam KP, et al. Genetic susceptibility to tuberculosis in Africans: A genome-wide scan. Proc Natl Acad Sci USA. 2000 ; 97: 8005-8009
23. Mitsos LM, Cardon LR, Ryan L, LaCourse R, North RJ, Gros P. Susceptibility to tuberculosis: A locus on mouse chromosome 19 (Trl-4) regulates Mycobacterium tuberculosis replication in the lungs. Proc Natl Acad Sci USA. 2003 ; 100: 6610-6615
24. Pan H, Yan BS, Rojas M, et al. Ipr1 gene mediates innate immunity to tuberculosis. Nature. 2005 ; 434: 767-772
25. Tosh K, Campbell SJ, Fielding K, et al. Variants in the SP110 gene are associated with genetic susceptibility to tuberculosis in West Africa. Proc Natl Acad Sci USA. 2006 ; 103: 10364-10368
26. Kampmann B, Hemingway C, Stephens A, et al. Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma. J Clin Invest. 2005 ; 115: 2480-2488
27. Badri M, Ehrlich R, Wood R, Pulerwitz T, Maartens G. Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area. Int J Tuberc Lung Dis. 2001 ; 5: 225-232
28. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001 ; 345: 1098-1104
29. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010 ; 69: 522-528
30. Shim TS. Diagnosis and treatment of latent tuberculosis infection due to initiation of anti-TNF therapy. Tuberc Respir Dis (Seoul). 2014 ; 76: 261-268
31. Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: A systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014 ; 73: 529-535
32. Dubaniewicz A. Mycobacterium tuberculosis heat shock proteins and autoimmunity in sarcoidosis. Autoimmun Rev. 2010 ; 9: 419-424
33. Rajaiah R, Moudgil KD. Heat shock proteins can promote as well as regulate autoimmunity. Autoimmun Rev. 2009 ; 8: 388-393
34. Saraav I, Singh S, Sharma S. Outcome of Mycobacterium tuberculosis and Toll-like receptor interaction: Immune response or immune evasion?. Immunol Cell Biol. 2014 ; 92: 741-746
35. Friendland JS, Shattock R, Remick DG, Griffin GE. Mycobacterial 65-kD heat shock protein induces release of proinflammatory cytokines from human monocytic cells. Clin Exp Immunol. 1993 ; 91: 58-62
36. Dubaniewicz A, Kämpfer S, Singh M. Serum anti-mycobacterial heat shock proteins antibodies in sarcoidosis and tuberculosis. Tuberculosis (Edinb). 2006 ; 86: 60-67
37. Dubaniewicz A, Trzonkowski P, Dubaniewicz-Wybieralska M, Dubaniewicz A, Singh M, Mys̈liwski A. Comparative analysis of mycobacterial heat shock proteins-induced apoptosis of peripheral blood mononuclear cells in sarcoidosis and tuberculosis. J Clin Immunol. 2006 ; 26: 243-250
38. Arrigo AP. Small stress proteins: Chaperones that act as regulators of intracellular redox state and programmed cell death. Biol Chem. 1998 ; 379: 19-26
39. Braian C, Hogea V, Stendahl O. Mycobacterium tuberculosis-induced neutrophil extracellular traps activate human macrophages. J Innate Immun. 2013 ; 5: 591-602
40. Nnoaham K, Clarke A. Low serum vitamin-D levels and tuberculosis: A systematic review and meta-analysis. Int J Epidemiol. 2008 ; 37: 113-119
41. Bornman L, Campbell S, Fielding K, et al. Vitamin-D receptor polymorphisms and susceptibility to tuberculosis in West Africa: A case-control and family study. J Infect Dis. 2004 ; 190: 1631-1641
42. Shapira Y, Agmon-Levin N, Shoenfeld Y. Mycobacterium tuberculosis, autoimmunity and vitamin D. Clin Rev Allerg Immunol. 2010 ; 38: 169-177
43. Borella E, Nesher G, Israeli E, Shoenfeld Y. Vitamin D: A new anti-infective agent?. Ann N Y Acad Sci. 2014 ; 1317: 76-83
44. Roth S, Delmont E, Heudier P, et al. Anti-TNF alpha monoclonal antibodies (infliximab) and tuberculosis: Apropos of 3 cases [article in French]. Rev Med Interne. 2002 ; 23: 312-316
45. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001 ; 345: 1098-1104
46. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet Infect Dis. 2003 ; 3: 148-155
47. Ehlers S. Why does tumour necrosis factor targeted therapy reactivate tuberculosis?. J Rheumatol Suppl. 2005 ; 74: 35-39
48. Ehlers S, Benini J, Kutsch S, Rietchel ET, Pfeffer K. Fatal granuloma necrosis exacerbated mycobacterial growth in tumor necrosis factor receptor p55 gene-deficient mice intravenously infected with Mycobacterium avium. Infect Immunity. 1999 ; 67: 3571-3579
49. Bean AG, Roach DR, Briscoe H, et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol. 1999 ; 162: 3504-3511
50. Buc M, Rovensky J Infection and autoimmunity. Shoenfeld Y Rose NR, ed. Amsterdam: Elsevier ; 2004: 623-628.
51. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010 ; 69: 522-528
52. Winthrop KL, Baxter R, Liu L, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis. 2013 ; 72: 37-42
53. Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y. Infections and autoimmunity - friends or foes?. Trends Immunol. 2009 ; 30: 409-414
54. Lancefield RC. Specific relationships of cell composition to biologic activity of hemolytic streptococci. Harvey Lect. 1941 ; 36: 251-265
55. von Herrath MG, Harrison LC. Antigen-induced regulatory T cells in autoimmunity. Nat Rev Immunol. 2003 ; 3: 223-232
56. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med. 2005 ; 353: 1261-1273
57. Lindor KD, Gershwin ME, Poupon R, Kaplan MM, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology. 2009 ; 50: 291-308
58. Bogdanos DP, Invernizzi P, Mackay IR, Vergani D. Autoimmune liver serology: Current diagnostic and clinical challenges. World J Gastroenterol. 2008 ; 14: 3374-3387
59. Bogdanos DP, Komorowski L. Disease-specific autoantibodies in primary biliary cirrhosis. Clin Chim Acta. 2011 ; 412: 502-512
60. Bogdanos DP, Vergani D. Bacteria and primary biliary cirrhosis. Clin Rev Allergy Immunol. 2009 ; 36: 30-39
61. Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis. 2002 ; 6: 727-737
62. Vilagut L, Vila J, Viñas O, et al. Cross-reactivity of anti-Mycobacterium gordonae antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis. J Hepatol. 1994 ; 21: 673-677
63. Gilburd B, Ziporen L, Zharhary D, et al. Antimitochondrial (pyruvate dehydrogenase) antibodies in leprosy. J Clin Immunol. 1994 ; 14: 14-19
64. Drebber U, Kasper HU, Ratering J, et al. Hepatic granulomas: Histological and molecular pathological approach to differential diagnosis - a study of 442 cases. Liver Int. 2008 ; 28: 828-834
65. Bogdanos DP, Pares A, Baum H, et al. Disease-specific cross-reactivity between mimicking peptides of heat shock protein of Mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. J Autoimmun. 2004 ; 22: 353-362
66. O'Donohue J, McFarlane B, Bomford A, Yates M, Williams R. Antibodies to atypical mycobacteria in primary biliary cirrhosis. J Hepatol. 1994 ; 21: 887-889
67. Statement on sarcoidosis. Am J Respir Crit Care Med. 1999 ; 160: 736-755
68. Dubaniewicz A, Dubaniewicz-Wybieralska M, Sternau A, et al. Mycobacterium tuberculosis complex and mycobacterial heat shock proteins in lymph node tissue from patients with pulmonary sarcoidosis. J Clin Microbiol. 2006 ; 44: 3448-3451
69. Trinchieri G. Regulatory role of T cells producing both interferon γ and interleukin 10 in persistent infection. J Exp Med. 2001 ; 194: F53 - F57
70. Jiang H, Chess L. Regulation of immune responses by T cells. N Engl J Med. 2006 ; 354: 1166-1176
71. Shoenfeld Y, Isenberg D. The mosaic of autoimmunity. Immunol Today. 1989 ; 10: 123-126
72. Fessler BJ. Infectious diseases in systemic lupus erythematosus: Risk factors, management and prophylaxis. Best Pract Res Clin Rheumatol. 2002 ; 16: 281-291
73. Gaipl US, Munoz LE, Grossmayer G, et al. Clearance deficiency and systemic lupus erythematosus (SLE). J Autoimmun. 2007 ; 28: 114-121
74. Lang KS, Burow A, Kurrer M, Lang PA, Recher M. The role of the innate immune response in autoimmune disease. J Autoimmun. 2007 ; 29: 206-212
75. Hill HM, Kirshbaum JD. Military tuberculosis developing during prolonged cortisone therapy of systemic lupus erythematosus. Ann Intern Med. 1956 ; 44: 781-790
76. Ribeiro FM, Szyper-Kravitz M, Klumb EM, et al. Can lupus flares be associated with tuberculosis infection?. Clin Rev Allergy Immunol. 2010 ; 38: 163-168
77. Ghosh K, Patwardhan M, Pradhan V. Mycobacterium tuberculosis infection precipitates SLE in patients from endemic areas. Rheumatol Int. 2009 ; 29: 1047-1050
78. Doria A, Canova M, Tonon M, et al. Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev. 2008 ; 8: 24-28
79. Sela O, el-Roeiy A, Isenberg DA, et al. A common anti-DNA antibody idiotype in sera of patients with active pulmonary tuberculosis. Arthritis Rheum. 1987 ; 30: 50-55
80. Asherson RA, Gunter K, Daya D, Shoenfeld Y. Multiple autoimmune diseases in a young woman: Tuberculosis and splenectomy as possible triggering factors? Another example of the "mosaic" of autoimmunity. J Rheumatol. 2008 ; 35: 1224-1226
81. Murray HW. Transient autoimmune hemo lytic anemia and pulmonary tuberculosis. N Eng J Med. 1978 ; 299: 488-488
82. Shoefeld Y, Vilner Y, Coates AR, et al. Monoclonal anti-tuberculosis antibodies react with DNA, and monoclonal anti-DNA autoantibodies react with Mycobacterium tuberculosis. Clin Exp Immunol. 1986 ; 6: 255-261
83. Flores-Suárez LF, Cabiedes J, Villa AR, van der Woude FJ, Alcocer-Varela J. Prevalence of antineutrophil cytoplasmic autoantibodies in patients with tuberculosis. Rheumatology (Oxford). 2003 ; 42: 223-229
84. Teixeira L, Mahr A, Jaureguy F, et al. Low seroprevalence and poor specificity of antineutrophil cytoplasmic antibodies in tuberculosis. Rheumatology (Oxford). 2005 ; 44: 247-250
85. Nakayama H, Uchida K, Sim JJ, et al. A case of pulmonary arteritis with stenosis of the main pulmonary arteries with positive myeloperoxidase-antineutrophil cytoplasmic autoantibodies. Respirology. 2000 ; 5: 381-384
86. Chaiamnuay S, Heck LW. Antineutrophil cytoplasmic antibody vasculitis associated with mycobacterium avium intracellulare infection. J Rheumatol. 2005 ; 32: 1610-1612
87. Faruqi S, Kastelik JA, McGivern DV. Diagnostic pitfall: Mycobacterium avium complex pulmonary infection and positive ANCA. Eur J Intern Med. 2008 ; 19: 216-218
88. De Clerck LS, Van Offel JF, Smolders WA, et al. Pitfalls with anti-neutrophil cytoplasmic antibodies (ANCA). Clin Rheumatol. 1989 ; 8: 512-516
89. Sherkat R, Mostafavizadeh K, Zeydabadi L, Shoaei P, Rostami S. Antineutrophil cytoplasmic antibodies in patients with pulmonary tuberculosis. Iran J Immunol. 2011 ; 8: 52-57
90. Kontic M, Radovanovic S, Nikolic M, Bonaci-Nikolic B. Concomitant drug- and infection-induced antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis with multispecific ANCA. Med Princ Pract. 2012 ; 21: 488-491
91. Schmitt WH, van der Woude FJ. Clinical applications of antineutrophil cytoplasmic antibody testing. Curr Opin Rheumatol. 2004 ; 16: 9-17
92. Elkayam O, Bendayan D, Segal R, et al. The effect of anti-tuberculosis treatment on levels of anti-phospholipid and anti-neutrophil cytoplasmatic antibodies in patients with active tuberculosis. Rheumatol Int. 2013 ; 33: 949-953
93. Elkayam O, Caspi D, Lidgi M, Segal R. Autoantibody profiles in patients with active pulmonary tuberculosis. Int J Tuberc Lung Dis. 2007 ; 11: 306-310
94. Adebajo AO, Charles P, Maini RN, Hazleman BL. Autoantibodies in malaria, tuberculosis and hepatitis B in a west African population. Clin Exp Immunol. 1993 ; 92: 73-76
95. McNally T, Purdy G, Mackie IJ, Machin SJ, Isenberg DA. The use of an anti-beta 2-glycoprotein-I assay for discrimination between anticardiolipin antibodies associated with infection and increased risk of thrombosis. Br J Haematol. 1995 ; 91: 471-473
96. Hunt JE, McNeil HP, Morgan GJ, Crameri RM, Krilis SA. A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus. 1992 ; 1: 75-81
97. Hojnik M, Gilburd B, Ziporen L, et al. Anticardiolipin antibodies in infections are heterogenous in their dependency on beta 2-glycoprotein I: Analysis of anticardiolipin antibodies in leprosy. Lupus. 1994 ; 3: 515-521
98. Elkayam O, Segal R, Lidgi M, Caspi D. Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis. Ann Rheum Dis. 2006 ; 65: 1110-1112
99. Elkayam O, Segal R, Bendayan D, van Uitert R, Onnekink C, Pruijn GJ. The anti-cyclic citrullinated peptide response in tuberculosis patients is not citrulline-dependent and sensitive to treatment. Arthritis Res Ther. 2010 ; 12: R12 - R12